Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Akebia Therapeutics to post earnings of ($0.03) per share and revenue of $44.88 million for the quarter.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The firm had revenue of $46.50 million for the quarter, compared to analyst estimates of $37.36 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Trading Down 4.5 %

NASDAQ:AKBA opened at $2.34 on Tuesday. The stock has a market capitalization of $612.58 million, a P/E ratio of -10.17 and a beta of 0.87. Akebia Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.89. The firm has a 50 day moving average of $2.01 and a 200-day moving average of $1.97.

Analyst Ratings Changes

Several analysts have recently commented on AKBA shares. Leerink Partnrs upgraded Akebia Therapeutics to a “strong-buy” rating in a report on Monday, April 28th. Leerink Partners assumed coverage on shares of Akebia Therapeutics in a research report on Monday, April 28th. They issued an “outperform” rating and a $7.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Akebia Therapeutics in a research note on Tuesday, April 1st. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $7.50 price target on shares of Akebia Therapeutics in a research note on Friday, April 4th. Finally, Piper Sandler boosted their price objective on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $6.63.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.